EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY

被引：0

作者：

Mease, P. J. ^{[1
,2
]}

Baraliakos, X. ^{[3
]}

Chandran, V. ^{[4
,5
]}

Soriano, E. ^{[6
]}

Nash, P. ^{[7
,8
]}

Deodhar, A. ^{[9
]}

Rampakakis, E. ^{[10
,11
]}

Shiff, N. ^{[12
,13
]}

Chakravarty, S. D. ^{[14
,15
]}

Shawi, M. ^{[16
]}

Merola, J. F. ^{[17
,18
]}

Mcinnes, I. ^{[19
]}

机构：

[1] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA

[3] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, Claudiusstr, Germany

[4] Univ Toronto, Toronto, ON, Canada

[5] Schroeder Arthrit Inst, Dept Med, Div Rheumatol, Toronto, ON, Canada

[6] Hosp Italiano Buenos Aires, Rheumatol, Buenos Aires, DF, Argentina

[7] Griffith Univ, Maroochydore, Australia

[8] Univ Queensland, Rheumatol Res Unit, Maroochydore, Australia

[9] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portand, OR USA

[10] McGill Univ, Dept Pediat, Montreal, PQ, Canada

[11] JSS Med Res Inc, Sci Affairs, Montreal, PQ, Canada

[12] Janssen Sci Affairs LLC, Immunol, Horsham, PA USA

[13] Univ Saskatchewan, Community Hlth & Epidemiol, Saskatoon, SK, Canada

[14] Janssen Sci Affairs LLC, Immunol, Horsham, PA USA

[15] Drexel Univ, Coll Med, Div Rheumatol, Philadelphia, PA 19104 USA

[16] Janssen Pharmaceut Co Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA

[17] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[18] Harvard Med Sch, Div Rheumatol & Immunol, Boston, MA 02115 USA

[19] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Clinical trials; Psoriatic arthritis; Outcome measures;

D O I：

10.1136/annrheumdis-2023-eular.642

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB1108

引用

页码：1782 / 1783

页数：2

共 50 条

[1] LONG-TERM IMPROVEMENT IN INDIVIDUAL ACR RESPONSE CRITERIA AND RESIDUAL DISEASE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST HOC ANALYSIS OF A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY
Nash, P.
Mcinnes, I.
Shawi, M.
Nantel, F.
Kollmeier, A.
Rampakakis, E.
Soriano, E.
Gladman, D. D.
Deodhar, A.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1769 - 1770
[2] Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Felten, Renaud
Widawski, Laura
Spielman, Lionel
Gottenberg, Jacques-Eric
Duret, Pierre-Marie
Rampakakis, Emmanouil
Sharaf, Mohamed
Constantin, Caren
Campana, Vincenza
Messer, Laurent
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4429 - 4432
[3] Efficacy of guselkumab in bionaive psoriatic arthritis patients with severe disease activity: post hoc analysis of Phase 3, randomized, double-blind, placebo-controlled study
Ritchlin, Christopher T.
Lubrano, Ennio
Chimenti, Maria Sole
Leibowitz, Evan
Sharaf, Mohamed
Rampakakis, Emmanouil
Chakravarty, Soumya
Nantel, Francois
Lavie, Frederic
Deodhar, Atul
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[4] Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Coates, Laura C.
Gossec, Laure
Zimmermann, Miriam
Shawi, May
Rampakakis, Emmanouil
Shiff, Natalie J.
Kollmeier, Alexa P.
Xu, Xie L.
Nash, Peter
Mease, Philip J.
Helliwell, Philip S.
RMD OPEN, 2024, 10 (01):
[5] Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Ritchlin, Christopher
Lubrano, Ennio
Chimenti, Maria Sole
Leibowitz, Evan
Sharaf, Mohamed
Adelakun, Oyediran
Rampakakis, Emmanouil
Nantel, Francois
Lavie, Frederic
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2999 - 3001
[6] Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study
Ritchlin, Christopher T.
Mease, Philip J.
Boehncke, Wolf-Henning
Tesser, John
Chakravarty, Soumya D.
Rampakakis, Emmanouil
Shawi, May
Schiopu, Elena
Merola, Joseph F.
McInnes, Iain B.
Deodhar, Atul
CLINICAL RHEUMATOLOGY, 2024, 43 (08) : 2551 - 2563
[7] Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Kavanaugh, Arthur
Soriano, Enrique
Dutz, Jan
Selmi, Carlo
Rampakakis, Emmanouil
Shiff, Natalie
Nantel, Francois
Lavie, Frederic
Coates, Laura
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4421 - 4424
[8] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Coates, Laura C.
Rahman, Proton
Mease, Philip J.
Shawi, May
Rampakakis, Emmanouil
Kollmeier, Alexa P.
Xu, Xie L.
Chakravarty, Soumya D.
McInnes, Iain B.
Tam, Lai-Shan
BMC RHEUMATOLOGY, 2024, 8 (01)
[9] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
Laura C. Coates
Proton Rahman
Philip J. Mease
May Shawi
Emmanouil Rampakakis
Alexa P. Kollmeier
Xie L. Xu
Soumya D. Chakravarty
Iain B. McInnes
Lai-Shan Tam
BMC Rheumatology, 8
[10] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Deodhar, Atul A.
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Zhuang, Yanli
Barchuk, William
Xu, Xie L.
Hsia, Elizabeth
ARTHRITIS & RHEUMATOLOGY, 2017, 69

← 1 2 3 4 5 →